REGIME
HIPAA-aware
Default workflow assumes PHI handling and medical-legal review on patient-facing assets.
SECTOR 02 — TECHNOLOGY & REGULATED
Healthcare
& Life SciencesCompliant brand and clinical-grade clarity for providers, payers, digital health, medtech, and life-science operators.
HIPAADigital-HealthMedtechPayer / Provider
02
Practice scope
Healthcare buyers — clinicians, payers, regulators, patients — share one trait: they read carefully and they remember. Marketing that overpromises gets noticed by the same people who decide whether you keep operating. We build brand and content systems that earn clinical credibility, move through medical-legal review without bottlenecks, and translate science into language an actual patient or buyer can act on.
- Engagement
- 12–20 wks · avg length
- Audience
- MLR-ready
- Disciplines
- Strategy · Brand · Build · Growth · Legal
- Adjacent industries
- Technology & Software · Insurance · Government & Public Sector
01
CH · 01 / 10 — Snapshot
The sector in four numbers and a posture.
Every industry opens with the same four-cell read: regime, engagement length, audience structure, and the operating signal that determines how this sector buys. Healthcare & Life Sciences is no exception.
AVG LENGTH
12–20 wks
Review cycles add weeks; engagements scope around them, not against them.
REVIEW
MLR-ready
Medical, legal, regulatory review built into the asset workflow from day one.
AUDIENCE
Multi-tier
Patient, clinician, payer, and investor — every asset family designed for its tier.
02
CH · 02 / 10 — Forces
Three forces reshaping healthcare & life sciences.
We don't open with claims about ourselves. We open with what's actually pressing on the operators we serve — the structural shifts that determine which kinds of brand and demand work compound this cycle and which don't.
FORCE 01
Clinical buyers want plain language
Physicians no longer read brochures designed by physicians. They read the patient-facing version because it's faster — and they expect it to be accurate.
FORCE 02
Payer math is the lock
Whether digital health, medtech, or pharma, the model has to clear a payer-grade financial review. Marketing that ducks the question loses the deal.
FORCE 03
Patients are platform-native
Mobile-first, comparison-shopping, post-scrolling patients evaluate health brands on the same surfaces they evaluate consumer ones. The standard moves up.
03
CH · 03 / 10 — Sub-sectors
Four families under one practice.
Healthcare & Life Sciences isn't one customer. It's four — and the engagement scope, audience, and creative language we ship varies materially across them. The industry covers all four; most engagements pick one.
01
Digital Health & Care
Telehealth, virtual-first care, chronic-condition platforms, behavioral health. Direct-to-patient with payer overlay.
02
Medtech & Devices
Class II/III devices, surgical robotics, in-vitro diagnostics. Clinical evidence drives every page.
03
Pharma & Biotech
Pre- and post-launch communication, MSL enablement, milestone & investor narrative.
04
Payers & Provider Systems
Health plans, IDNs, ACO operators. Member acquisition, network communication, value-based care narrative.
04
CH · 04 / 10 — Buyer-side
Who we actually work with.
Most marketing decks address an "audience". We address a person — usually one of three, with a budget, a quarter to defend, and a specific frustration with the marketing they've been shipped before. These are them.
CMO / VP MARKETING
Owning the patient story
Building patient-facing brand that survives MLR and lifts conversion at the same time.
“We need to sound like humans — and still pass review.”
CHIEF COMMERCIAL OFFICER
Payer + provider GTM
Designing parallel narratives for clinical buyers and benefits leaders.
“Two audiences, one product, neither hears the same pitch.”
FOUNDER / CEO
Investor & milestone story
Translating clinical evidence into a story the next round will fund.
“The data is strong. The deck reads like a journal article.”
05
CH · 05 / 10 — Problems
Six problems we solve repeatedly.
Industry-specific, not generic. Each of these has been the headline problem on multiple healthcare & life sciences engagements, and the work below is purpose-built for the regime, audience, and review cycle this sector lives inside.
P · 01
Compliant patient-facing content
Patient education, consent flows, and marketing that meets HIPAA, ADA, and PhRMA-equivalent guidance.
P · 02
Clinical-to-consumer translation
Turning peer-reviewed evidence into messaging clinicians vouch for and patients understand on first read.
P · 03
Payer & provider GTM
Dual-track sales motion with payer-grade ROI math and clinician credibility content.
P · 04
Trial recruitment funnels
Patient identification, eligibility screening, and consent — at speed without slipping IRB constraints.
P · 05
Milestone & investor messaging
FDA filings, readouts, partnership announcements written for both regulators and capital markets.
P · 06
Medical-legal review workflow
Tooling and process that lets MLR ship in days, not months — without lowering the bar.
P · 07
Brand for regulated launches
Identity and content systems that span clinical, commercial, and patient teams without fragmenting.
P · 08
Health-system buyer enablement
RFP responses, security packets, and ROI calculators tuned to enterprise-health procurement.
06
CH · 06 / 10 — Engagement
Five deliverables we ship in this sector.
An engagement is a stack of these — chosen against your problem, your timeline, and the disciplines we need to bring. Most healthcare & life sciences engagements pick three to five and run them in coordinated phases.
STRATEGY
Brand + regulatory review workflow
MLR / PRC operating model and the tooling that makes it move.
BRAND
Patient & clinician journey maps
Friction-point analysis with content and product implications mapped.
BUILD
Medical-legal content system
Library, claims management, citation handling, and review states.
GROWTH
Clinical / product launch package
Clinician, patient, payer, and press tracks on a single calendar.
STRATEGY
Investor & board narrative
Story that holds up in front of FDA, KOLs, and a tier-1 fund in the same week.
BUILD
Patient acquisition site & funnels
Conversion-led, accessibility-compliant, instrumented for outcomes.
07
CH · 07 / 10 — Blend
Discipline weighting for healthcare & life sciences.
Every sector pulls on our five disciplines differently. This is the calibrated weighting — the dosing we default to on a typical engagement, before we adjust to your specific brief.
The weighting reads left-to-right as the share of senior-team focus on a default engagement. This sector is regulated, so legal-and-compliance work is ranked first-class — not as a sign-off step. No discipline disappears entirely; the ratio is what changes.
08
CH · 08 / 10 — Outcomes
Four outcomes we measure on.
Numbers below are anonymized engagement medians from comparable healthcare & life sciences cohorts. Every one of them traces back to a named brief, a measurement window, and a method we'll walk you through in person before you commit to anything.
MLR THROUGHPUT
3.2×
Median assets-per-month after review system rebuild.
PATIENT ACQUISITION
+47%
Conversion lift on patient-facing journeys after redesign.
PAYER WINS
+24%
Win-rate lift on benefits-leader audience post-narrative work.
TIME TO MARKET
−6wks
Median launch-cycle compression on commercial-stage products.
09
CH · 09 / 10 — Sector FAQ
Things we get asked every intake.
A short list of the questions healthcare & life sciences buyers ask us before signing. If you've been here before, the rest of the process will feel familiar; if you haven't, this is a useful first read.
FAQ · 01
Do you handle MLR yourself or sit alongside it?
Both. We build the workflow, train the tooling, and sit inside it as a team — but final review remains with your medical, legal, and regulatory counsel. The improvement is throughput, not delegation of judgment.
FAQ · 02
Can you work in HIPAA-covered environments?
Yes. Our default agreements include BAA-ready language and our delivery environments are configured for PHI handling. Specific platform integrations are scoped in week one.
FAQ · 03
We're pre-FDA approval. Is now too early?
No. The brand and message work that holds up at launch is decided eighteen months earlier. We frequently engage post-Phase II / pre-pivotal — and revisit at submission and launch.
FAQ · 04
Do you do scientific writing?
Not peer-reviewed manuscripts or regulatory submissions. We translate from those documents into commercial, patient-facing, and investor narratives — and we work alongside your medical writers, not over them.
FAQ · 05
How do you handle international regulation?
We default to FDA / FTC / HIPAA in the US and EMA / GDPR in EU jurisdictions. Country-specific work is scoped with local counsel; we don't pretend to substitute for it.
10
CH · 10 / 10 — Adjacents
Other industries worth pulling.
Healthcare & Life Sciences doesn't sit in isolation. These are the practice groups we most often run alongside it — operators who share buyer audiences, regulatory regimes, or commercial dynamics with the work covered above.
SECTOR 01 · TECHNOLOGY & REGULATED
Technology & Software
Positioning, GTM, and product-led growth for teams shipping software — from seed-stage SaaS to platform incumbents
PULL INDUSTRY →
SECTOR 20 · FINANCIAL & PROFESSIONAL
Insurance
Broker-vs-direct plays, claims UX, and regulated lifecycle content for P&C, life, health, and specialty insurance
PULL INDUSTRY →
SECTOR 19 · PUBLIC & MISSION-LED
Government & Public Sector
Program clarity, citizen-facing UX, and procurement-ready collateral for agencies, GovTech vendors, and municipal operators
PULL INDUSTRY →
If your team operates in healthcare & life sciences,
this is what an intake looks like.
One 45-minute call with a partner, no slides. We use the time to map your problem to the chapters in this industry and tell you — honestly — whether we're the right team for it. The answer is sometimes no, which is part of why our clients send other clients.